A Phase 1 Open-Label Study to Evaluate the Safety Tolerability and Activity of AK002 in Patients with Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

This study is being done to see how safe the investigational new drug, AK002 is and how it affects your EG and/or EGE symptoms and the number of eosinophils in the stomach and the small intestine. This study will also be used to identify the best premedication and dose regimen to use in patients in future research studies.

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Gastroenteritis
• Age: - 99 Years
• Gender: All